NCT00635024View on ClinicalTrials.gov

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

November 30, 2010

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

anti-thymocyte globulin

2.5 mg/kg

DRUG

melphalan

16 mg/m\^2

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER